Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.

Abdul Rafeh NaqashJustin D McCallenEmma MiSanna IivanainenMona A MarieDaria GramenitskayaJames ClarkJussi Pekka KoivunenShravanti MacherlaSweta JonnalagaddaShanker PolsaniRahim Ali JiwaniMaida HafizMahvish MuzaffarLeonardo BrunettiChipman R G StroudPaul R WalkerKun WangYoungmin ChungEytan RuppinSe-Hoon LeeLi V YangDavid James PinatoJoo Sang LeeAlessio Cortellini

Published in: Journal for immunotherapy of cancer (2023)

This study demonstrates CRP as a readily available blood-based prognostic biomarker in ICI-treated NSCLC. Additionally, we elucidate a potential link of the CRP/IL-6 axis with the immunosuppressive adenosine signature pathway that could drive inferior outcomes to ICIs in NSCLC and also offer novel therapeutic avenues.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
human health
protein kinase
cell proliferation
poor prognosis
signaling pathway
metabolic syndrome
newly diagnosed
climate change